Company Monitoring Page for Eisai

job ratings for Eisai

11/18/19
industry:
Big Pharma
company:
Eisai
job rating:
1
bad management
03/19/18
industry:
Big Pharma
company:
Eisai
job rating:
2
Micro managers
04/04/17
industry:
Neurology pharmaceutical Sales
job title:
Neurology salespecially specialist
company:
Eisai
job rating:
1
Poor pay, awful management, no respect for current reps kept through downsizing

latest headlines for company on cafepharma

Eisai unit hands over $46M for Japanese rights to Newron’s schizophrenia add-on
Fierce Biotech
Sun, 12/15/24 - 10:48 pm
Tags:
Newron Pharma, Eisai, schizophrenia, evenamide
Eisai sunsets development, access program for withdrawn obesity med in Dravet syndrome
Fierce Pharma
Mon, 11/18/24 - 06:36 pm
Tags:
Eisai, obesity, lorcaserin
Eisai wins over European regulators on Alzheimer’s drug Leqembi
BioPharma Dive
Thu, 11/14/24 - 10:28 pm
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease
Eisai Cuts Fiscal 2024 Guidance for Biogen-Partnered Leqembi as Sales Disappoint Analysts
BioSpace
Sun, 11/10/24 - 09:27 pm
Tags:
Eisai, Biogen, Leqembi, earnings, Alzheimer's disease
Eisai dials back forecasts for Alzheimer's drug Leqembi
Pharmaphorum
Fri, 11/8/24 - 11:38 am
Tags:
Eisai, earnings, Leqembi, Alzheimer's disease
Eisai, Biogen eye 2025 approval for Leqembi autoinjector
Pharmaphorum
Fri, 11/1/24 - 10:57 am
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease, FDA
Leqembi's vial design could result in hundreds of millions in annual Medicare waste: study
Fierce Pharma
Mon, 10/14/24 - 11:13 pm
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease
ESMO: Despite checkered past, Merck's Keytruda-Lenvima pairing looks to change practice in liver cancer subtype
Fierce Pharma
Sun, 09/15/24 - 06:30 pm
Tags:
ESMO, Merck, Eisai, Keytruda, Lenvima, liver cancer
Eisai, Biogen's Leqembi nabs UK nod, but reimbursement remains elusive
Fierce Pharma
Thu, 08/22/24 - 11:45 am
Tags:
Eisai, Biogen, Leqembi, UK, Alzheimer's disease
Eisai plants molecular glue SEED with $1.5B biobucks deal in neuro, oncology
Fierce Biotech
Tue, 08/6/24 - 11:14 am
Tags:
Eisai, molecular glue, biobucks, Seed Therapeutics
After EU setback, Eisai/Biogen build case for Leqembi
Pharmaphorum
Wed, 07/31/24 - 10:25 am
Tags:
Eisai, Biogen, Alzheimer's disease, Leqembi, Europe
Eisai 'extremely disappointed' by EMA's decision on Alzheimer's drug
Biopharma Reporter
Tue, 07/30/24 - 11:37 am
Tags:
Eisai, EMA, Europe, Leqembi, Biogen, Alzheimer's disease
Eisai and Biogen's Alzheimer's med Leqembi turned down in Europe
Fierce Pharma
Fri, 07/26/24 - 11:15 am
Tags:
Eisai, Biogen, Leqembi, Europe
Eisai adopts Medidata’s AI-driven platform for clinical trials
Clinical Trials Arena
Fri, 07/26/24 - 11:13 am
Tags:
Eisai, Medidata, clinical trials, artificial intelligence
Leqembi sales inch higher; Spark’s pivot leads to layoffs
BioPharma Dive
Fri, 07/12/24 - 11:29 am
Tags:
Eisai, Biogen, Leqembi, Alzheimer's disease, Roche, Spark Therapeutics, gene therapy, layoffs
Leqembi gains approval for Alzheimer’s treatment in Israel
Pharmaceutical Business Review
Fri, 07/12/24 - 11:12 am
Tags:
Eisai, Israel, Alzheimer's disease, Leqembi, BioArctic
BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival
Fierce Biotech
Mon, 07/1/24 - 11:29 am
Tags:
Bristol Myers Squibb, Eisai, antibody-drug conjugate
Eisai and Biogen launch Alzheimer's drug Leqembi in China
Reuters
Fri, 06/28/24 - 11:18 am
Tags:
Eisai, Biogen, Alzheimer's disease, Leqembi, China
Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections
Pharma Voice
Fri, 06/28/24 - 11:17 am
Tags:
Big Pharma, Neuroscience, Prothena Biosciences, Biogen, Eisai, Pfizer, AbbVie, Eli Lilly, Bristol Myers Squibb
What Would a Donanemab Approval Mean for Leqembi?
BioSpace
Mon, 06/24/24 - 10:47 am
Tags:
Eli Lilly, donanemab, Biogen, Eisai, Leqembi, FDA, Alzheimer's disease

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.